BioCentury
ARTICLE | Emerging Company Profile

AAVs for the CNS

Voyager developing AAV-based gene therapies for CNS disorders

March 9, 2015 7:00 AM UTC

Voyager Therapeutics Inc. has a pipeline of adeno-associated viral vector-based gene therapies and is developing novel vectors that are optimized for better distribution in the CNS, among other qualities.

Third Rock Ventures launched Voyager about a year ago. The newco has one program in the clinic and four programs in preclinical development. All but one are optioned to Genzyme Corp. under a February deal. ...